HEALTH AND MEDICINE COUNSEL for MARFAN FOUNDATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 9, 2020 | $10,000 | Replaced |
| 1st Quarter - Report | Apr 9, 2020 | $10,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Marfan Syndrome Research activities at NIH Marfan Syndrome Education & Awareness & Screening activities at CDC Patients Access to Treatments Act 21st Century Cures Implementation Healthcare Reform, Patient Protections RARE Act COVID-19 Relief Packages
| Lobbyist | Covered position, as disclosed |
|---|---|
| DALE P DIRKS | Legislative Consultant |
| PHILIP GOGLAS | Legislative Consultant |
Budget/Appropriations BUD
FY20 & FY21 L-HHS Appropriations (Biomedical Research & Public Health Programs) COVID-19 Supplemental Appropriations COVID-19 Legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DALE P DIRKS | Legislative Consultant |
| PHILIP GOGLAS | Legislative Consultant |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.